Metabolic Regulation of Immune Responses: Molecular Mechanisms, Diseases, and Therapeutic Targets
MedComm · 2026-06 · 7 (6)
DOI: 10.1002/mco2.70801 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 08.06.2026. Verfasst von Chunwei Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Laboratory for Internet Medical Systems and Applications The First Affiliated Hospital of Zhengzhou University Zhengzhou China. Die Arbeit nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer‐associated metabolic reprogramming profoundly reshapes the tumor microenvironment (TME), emerging as a central driver of immune evasion and therapeutic resistance. Increasing evidence indicates that metabolic enzymes function not only as bioenergetic regulators but also as active modulators of immune signaling, immune cell fate, and immune checkpoint expression. To elucidate these complex immunometabolic networks, this review utilizes fructose‐1,6‐bisphosphatase 1 (FBP1)—a key gluconeogenic enzyme—as a paradigmatic metabolic gatekeeper to illustrate how metabolic dysregulation drives tumor progression. By examining both the canonical metabolic effects and noncanonical signaling mechanisms of such enzymes, we synthesize recent advances demonstrating how metabolic rewiring promotes glycolytic reprogramming, immune suppression, and resistance to immunotherapy. Specifically, we explore broad mechanisms of immune evasion, including STAT3–PD‐L1 regulation, modulation of innate immune surveillance, T cell exhaustion, and remodeling of stromal and fibrotic tumor niches. Furthermore, we discuss emerging therapeutic strategies targeting these immunometabolic pathways, encompassing small‐molecule modulators, vitamin‐ and gene‐based interventions, nanotechnology‐enabled delivery systems, and metabolism‐informed combination immunotherapy. Finally, we highlight key challenges, including metabolic heterogeneity and context‐dependent enzyme function, emphasizing the need for biomarker‐guided precision strategies to translate fundamental immunometabolic insights into durable and safe cancer therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Engineering Laboratory for Internet Medical Systems and Applications The First Affiliated Hospital of Zhengzhou University Zhengzhou China.
- Department of Pharmacology Henan Provincial People's Hospital Zhengzhou China.
- Department of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou China.
- Colorectal Cancer Center Department of General Surgery West China Hospital Sichuan University Chengdu China.
- The First Affiliated Hospital of Zhengzhou University Zhengzhou China.
- Zhengzhou University First Affiliated Hospital Department of Radiation Oncology Zhengzhou China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, C., Liu, Z., Kong, D., Li, Z., Yan, Y., Dong, Y., Zhu, L., Cao, J., Fan, Z., Sethi, G., & Li, L. (2026). Metabolic Regulation of Immune Responses: Molecular Mechanisms, Diseases, and Therapeutic Targets. MedComm, 7(6). https://doi.org/10.1002/mco2.70801
Vancouver
Li C, Liu Z, Kong D, Li Z, Yan Y, Dong Y, et al. Metabolic Regulation of Immune Responses: Molecular Mechanisms, Diseases, and Therapeutic Targets. MedComm. 2026;7(6). doi:10.1002/mco2.70801
BibTeX
@article{Li2026,
author = {Li, Chunwei and Liu, Ziqiang and Kong, Dezheng and Li, Zhengze and Yan, Yiming and Dong, Yanyu and Zhu, Lili and Cao, JiaNing and Fan, Zhirui and Sethi, Gautam and Li, Lifeng},
title = {Metabolic Regulation of Immune Responses: Molecular Mechanisms, Diseases, and Therapeutic Targets},
journal = {MedComm},
year = {2026},
volume = {7},
number = {6},
doi = {10.1002/mco2.70801}
}
EUVIMED